Welcome to the e-CCO Library!

P592 Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis in conditions of real clinical practice
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Knyazev, A. Kagramanova, A. Lishchinskaya, A. Parfenov

Created: Thursday, 30 January 2020, 10:12 AM
P592: Clinical evaluation of leukocytapheresis compared to vedolizumab in patients with Ulcerative Colitis with contraindications to anti-TNF-alpha: a single-centre experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ferronato, A.(1)*;Rigno, M.(2);Rodriguez-Castro, K.I.(1);Brozzi, L.(1);Errigo, G.(2);Castelli, M.(2);Baldassarre, G.(1);
Created: Friday, 14 July 2023, 11:05 AM
P592: Costs savings associated with ferric maltol and the reduced use of intravenous iron based on real world data
Year: 2021
Source: ECCO'21 Virtual
Authors: Howaldt, S.(1,2,3);Becker, C.K.(4);Becker, J.A.(4);Poinas , A.C.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P592: Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients
Year: 2022
Source: ECCO'22
Authors: Crouwel, F.(1);Bayoumy, A.B.(1);Mulder, C.J.J.(1);Peters, J.H.C.(2);Boekema, P.J.(3);Derijks, L.J.J.(4);De Boer, S.Y.(5);van de Meeberg, P.C.(5);Ahmad, I.(6);Buiter, H.J.C.(7);de Boer, N.K.(1);
Created: Friday, 11 February 2022, 3:56 PM
P592: Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Vinayaga-Pavan*, T. Kumagai, I. Parisi, J. Barragry, R. Sundramoorthi, L. Whitley, H. Parker, R. Kettle, N. McCabrey, E. Steward, S. McCartney, S. Bloom, R. Vega, S. Mehta, F. Rahman

Created: Thursday, 21 February 2019, 9:14 AM
P592: Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lovasz B.D.*1, Kurti Z.1, Rutka M.2, Vegh Z.1, Gecse K.B.1, Farkas K.2, Banai J.3, Bene L.4, Golovics P.A.1, Gonczi L.1, Gasztonyi B.5, Kristof T.6, Lakatos L.7, Miheller P.8, Palatka K.9, Patai A.10, Papp M.9, Salamon A.11, Szamosi T.3, Szepes Z.2, Toth G.T.12, Vincze A.13, Szalay B.14, Molnar T.2, Lakatos P.L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P592: Towards a Food Pharmacy: increased dietary quality reduces CRP and improves quality of life in IBD patients in remission
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Molendijk*1, J. E. Martens1, E. van Lingen1, S. van der Marel1, M. E. van Veen-Lievaart2, A. E. van der Meulen1, M. C. Barnhoorn1, A. M. Ernst-Stegeman3, J. Maljaars1

Created: Friday, 22 February 2019, 9:41 AM
P593 Predictors of steroid-resistance in severe colitis of inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. JEMMALI1, A. Labidi2, M.A. Jouini2, M. Hafi2, M. Serghini2, M. Fekih2, J. Boubaker2

Created: Thursday, 30 January 2020, 10:12 AM
P593: A national database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. E. Stellingwerf*1, W. A. Bemelman1, G. R. D'Haens2, C. Y. Ponsioen2, C. J. Buskens1

Created: Friday, 22 February 2019, 9:41 AM
P593: Biologicals and small molecule combotherapies: promising experience in refractory IBD patients
Year: 2022
Source: ECCO'22
Authors: JuilleratMSc, P.(1);Martinho-Grueber, M.(1);Michetti, P.(2);
Created: Friday, 11 February 2022, 3:56 PM
P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Briot1*, P. Faure2, A.L. Parmentier1, C. Gay1, C. Trang3, M. Nachury4, S. Viennot5, R. Altwegg6, P. Bulois7, L. Thomassin8, M. Serrero9, P. Ah Soune10, C. Gilletta11, L. Plastaras12, M. Simon13, X. Dray14, L. Caillo15, E. Del Tedeco16, V. Abitbol17, C. Zallot18, T. Degand19, V. Rossi20, G. Bonnaud21, D. Colin22, B. Morel23, J.B. Danset24, B. Winkfield25, J. Filippi26, A. Amiot27, A. Attar28, A. Bourreille29, J.C. Grimaud9, A. Blain30, L. Peyrin Biroulet18, L. Vuitton1

Created: Thursday, 21 February 2019, 9:14 AM
P593: Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hickey J.1, Keshav S.2,3, Gaugris S.4, Arasaradnam R.*5

Created: Wednesday, 20 February 2019, 10:36 AM
P593: Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Geldof, J.(1)*;Truyens, M.(2);Sabino, J.(3);Ferrante, M.(3);Lambert, J.(4);Lapeere, H.(4);Hillary, T.(5);Van Laethem, A.(5);de Vlam, K.(6);Verschueren, P.(6);Padalko, E.(7);Lobaton, T.(2);Vermeire, S.(3);
Created: Friday, 14 July 2023, 11:05 AM
P593: Ustekinumab for the treatment of perianal Crohn’s disease. A real-world experience in a Spanish hospital
Year: 2021
Source: ECCO'21 Virtual
Authors: Algara San Nicolas, M.(1);Masedo Gonzalez, A.(1);Gomez Gomez, G.J.(1);Yela San Bernardino, C.(1);Casis Herce, B.(1);Martinez Montiel, M.P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P594 Increased levels of stress, anxiety and depression among patients with CD and UC
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Laoudi1, D. Papalouka2, M. Gkizis1, G. Kokkotis1, N. Perlepe1, I. Vlachogiannakos3, I. Papakonstantinou2, G. Bamias1

Created: Thursday, 30 January 2020, 10:12 AM
P594: Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Maeda, M.(1)*;Sagami, S.(1,2);Tashima, M.(1);Yamana, Y.(1);Karashima, R.(1,2);Miyatani, Y.(1);Hojo, A.(1,2);Nakano, M.(1,2);Hibi, T.(1);Kobayashi, T.(1,2,3);
Created: Friday, 14 July 2023, 11:05 AM
P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Panés1*, D. García-Olmo2, A. Parfionovas3, C. Agboton4, J.M. Khalid5

Created: Thursday, 21 February 2019, 9:14 AM
P594: Predictors of non-response to repeated faecal microbiota transplantation in patients with therapy refractory ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Blesl*1, F. Rainer1, P. Wurm1, M. Durdevic1, W. Petritsch1, H. Wenzl1, F. Baumann-Durchschein1, A. Posch1, A. Streit1, G. Gorkiewicz1, H-P. Gröchenig2, P. Kump1, C. Högenauer1

Created: Friday, 22 February 2019, 9:41 AM
P594: Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rowan C.R.*1, Alakkari A.2, Moran C.3, O'Connell J.4, Cullen G.1, Mulcahy H.1, O'Morain C.2, McNamara D.2, Leyden J.5, MacMathuna P.5, O'Toole A.3, Patchett S.3, McKiernan S.4, Kevans D.4, Doherty G.A.1, Ryan B.2

Created: Wednesday, 20 February 2019, 10:36 AM
P594: Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience
Year: 2021
Source: ECCO'21 Virtual
Authors: Chiu, L.(1);Digby-Bell, J.(2);Seah, J.(1,3);Melton, S.(1,4);Taylor, K.(1,2);Sparrow, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM